D. Swinney

发表

How were new medicines discovered?

D. Swinney, J. Anthony, 2011, Nature Reviews Drug Discovery.

Insights into kinetic mechanism of Janus kinase 3 and its inhibition by tofacitinib.

D. Swinney, E. Fang, M. Hekmatnejad, 2016, Archives of biochemistry and biophysics.

Collaboration for rare disease drug discovery research

S. Ekins, D. Swinney, N. Litterman, 2014, F1000Research.

Biochemical mechanisms of drug action: what does it take for success?

D. Swinney, David C. Swinney, 2004, Nature Reviews Drug Discovery.

A study of the molecular mechanism of binding kinetics and long residence times of human CCR5 receptor small molecule allosteric ligands

D. Swinney, Jun Zhang, P. Beavis, 2014, British journal of pharmacology.

The role of binding kinetics in therapeutically useful drug action.

D. Swinney, 2009, Current opinion in drug discovery & development.

Pharmaceutical Industry Performance

D. Swinney, 2017 .

Molecular Mechanism of Action (MMoA) in Drug Discovery

D. Swinney, 2011 .

Contrasting Roles of Mitogen-Activated Protein Kinases in Cellular Entry and Replication of Hepatitis C Virus: MKNK1 Facilitates Cell Entry

D. Swinney, S. Lemon, M. Yi, 2013, Journal of Virology.

Biochemical characterization of the inhibition of the dengue virus RNA polymerase by beta-d-2'-ethynyl-7-deaza-adenosine triphosphate.

D. Swinney, A. Kutach, D. Shaw, 2010, Antiviral research.

Structural Characterization of Arachidonyl Radicals Formed by Prostaglandin H Synthase-2 and Prostaglandin H Synthase-1 Reconstituted with Mangano Protoporphyrin IX*

D. Swinney, A. Tsai, G. Palmer, 1998, The Journal of Biological Chemistry.

The Dynamics of Prostaglandin H Synthases

D. Swinney, O. So, L. Scarafia, 1998, The Journal of Biological Chemistry.

Cyclosporine metabolism by rat liver microsomes. Evidence for involvement of enzyme(s) other than cytochromes P-450 3A.

L. Benet, D. Swinney, A. Rettie, 1993, Drug metabolism and disposition: the biological fate of chemicals.

Transcriptomic analysis of the woodchuck model of chronic hepatitis B

Donavan T. Cheng, B. Taillon, Yongmei Ji, 2012, Hepatology.

Kinetic Binding Mechanisms: Their Contribution to an Optimal Therapeutic Index

D. Swinney, 2011 .

Selective inhibition of mammalian lanosterol 14 alpha-demethylase by RS-21607 in vitro and in vivo.

D. Swinney, P. Berry, K. A. Walker, 1994, Biochemistry.

A novel rat hepatic clofibrate-inducible cytochrome P450 that is not a lauric acid hydroxylase.

D. Swinney, A. Webb, R. Freedman, 1991, Biochemical pharmacology.

Selective inhibition of mammalian lanosterol 14 alpha-demethylase: a possible strategy for cholesterol lowering.

D. Swinney, D. Rotstein, P. Berry, 1993, Journal of medicinal chemistry.

Progesterone metabolism in hepatic microsomes. Effect of the cytochrome P-450 inhibitor, ketoconazole, and the NADPH 5 alpha-reductase inhibitor, 4-MA, upon the metabolic profile in human, monkey, dog, and rat.

D. Swinney, 1990, Drug metabolism and disposition: the biological fate of chemicals.

Stereoisomers of ketoconazole: preparation and biological activity.

D. Swinney, D. Rotstein, K. A. Walker, 1992, Journal of medicinal chemistry.

Intramolecular isotope effects associated with meta-hydroxylation of biphenyl catalyzed by cytochrome P-450.

D. Swinney, W. Trager, W. Howald, 1984, Biochemical and biophysical research communications.

Can Binding Kinetics Translate to a Clinically Differentiated Drug? From Theory to Practice

D. Swinney, 2006 .

Cigarette smoke synergistically enhances respiratory mucin induction by proinflammatory stimuli.

D. Swinney, K. Dabbagh, T. Baginski, 2006, American journal of respiratory cell and molecular biology.

Steady state kinetics of spleen tyrosine kinase investigated by a real time fluorescence assay.

D. Swinney, D. Shaw, J. Barnett, 2007, Biochemistry.

Recent advances in phenotypic drug discovery [version 1; peer review: 2 approved]

D. Swinney, Jonathan Lee, 2022 .

The Kinetic Factors That Determine the Affinity and Selectivity for Slow Binding Inhibition of Human Prostaglandin H Synthase 1 and 2 by Indomethacin and Flurbiprofen (*)

D. Swinney, O. So, O. Callan, 1996, The Journal of Biological Chemistry.

Differential Allosteric Regulation of Prostaglandin H Synthase 1 and 2 by Arachidonic Acid*

D. Swinney, J. Barnett, C. Ramesha, 1997, The Journal of Biological Chemistry.

Thermodynamics and Binding Kinetics in Drug Discovery

G. Keserü, D. Swinney, 2015 .

Mechanism of androstenedione formation from testosterone and epitestosterone catalyzed by purified cytochrome P-450b.

D. Swinney, P. Thomas, P. Hall, 1988, The Journal of biological chemistry.

Enzyme Activity Assays for Protein Kinases: Strategies to Identify Active Substrates.

D. Swinney, Brad A. Haubrich, 2016, Current drug discovery technologies.

3-Amino-pyrazolo[3,4-d]pyrimidines as p38α kinase inhibitors: design and development to a highly selective lead.

A. Kuglstatter, M. Stahl, D. Swinney, 2011, Bioorganic & medicinal chemistry letters.

Glycogen Synthase Kinase 3β Promotes the Endocytosis of Transferrin in the African Trypanosome.

D. Swinney, M. Pollastri, P. Guyett, 2016, ACS infectious diseases.

Kinetic characterization of human JNK2alpha2 reaction mechanism using substrate competitive inhibitors.

D. Swinney, Fengrong Zuo, Patricia Tran, 2007, Biochemistry.

Accumulation of intermediates and isotopically sensitive enolization distinguish between aromatase (cytochrome P450 CYP19) from rat ovary and human placenta.

D. Swinney, O. So, D. M. Watson, 1993, Archives of biochemistry and biophysics.

Evidence for concerted kinetic oxidation of progesterone by purified rat hepatic cytochrome P-450g.

D. Swinney, P. Thomas, W. Levin, 1988, Biochemistry.

Isotopically labeled chlorobenzenes as probes for the mechanism of cytochrome P-450 catalyzed aromatic hydroxylation.

D. Swinney, W. Trager, K. Korzekwa, 1989, Biochemistry.

Regioselective progesterone hydroxylation catalyzed by eleven rat hepatic cytochrome P-450 isozymes.

D. Swinney, P. Thomas, W. Levin, 1987, Biochemistry.

Fluxes for Unraveling Complex Binding Mechanisms.

D. Maes, D. Swinney, G. Vauquelin, 2020, Trends in pharmacological sciences.

On the different experimental manifestations of two‐state ‘induced‐fit’ binding of drugs to their cellular targets

D. Swinney, G. Vauquelin, I. Van Liefde, 2016, British journal of pharmacology.

The discovery of medicines for rare diseases.

D. Swinney, S. Xia, 2014, Future medicinal chemistry.

Intrahepatic Transcriptional Signature Associated with Response to Interferon-α Treatment in the Woodchuck Model of Chronic Hepatitis B

D. Swinney, H. Bitter, P. Ravindran, 2015, PLoS pathogens.

Quantitative expression analysis of the cellular specificity of HECT-domain ubiquitin E3 ligases.

D. Swinney, L. Scarafia, A. Winter, 2000, Physiological genomics.

of HECT-domain ubiquitin E 3 ligases Quantitative expression analysis of the cellular specificity

D. Swinney, A. Winter, 2000 .

Androgen formation by cytochrome P450 CYP17. Solvent isotope effect and pL studies suggest a role for protons in the regulation of oxene versus peroxide chemistry.

D. Swinney, A. Y. Mak, David C. Swinney, 1994, Biochemistry.

Recent advances in phenotypic drug discovery

D. Swinney, Jonathan A. Lee, 2020, F1000Research.

The Contribution of Mechanistic Understanding to Phenotypic Screening for First-in-Class Medicines

D. Swinney, David C Swinney, 2013, Journal of biomolecular screening.

Activation Mechanism and Steady State Kinetics of Bruton's Tyrosine Kinase*

J. M. Bradshaw, D. Swinney, D. Shaw, 2007, Journal of Biological Chemistry.

Essential Role of the N-terminal Domain in the Regulation of RIG-I ATPase Activity*

D. Swinney, P. Gee, J. Deval, 2008, Journal of Biological Chemistry.

The biopharmaceutics risk assessment roadmap for optimizing clinical drug product performance.

Anette Müllertz, Arzu Selen, Hans Lennernäs, 2014, Journal of pharmaceutical sciences.

A Small Molecule Ubiquitination Inhibitor Blocks NF-κB-dependent Cytokine Expression in Cells and Rats*

D. Swinney, J. Barnett, Ina Lee, 2002, The Journal of Biological Chemistry.

Targeting protein ubiquitination for drug discovery. What is in the drug discovery toolbox?

D. Swinney, 2001, Drug discovery today.

Pharmacology of a Ca(2+)-influx pathway activated by emptying the intracellular Ca2+ stores in HL-60 cells: evidence that a cytochrome P-450 is not involved.

D. Swinney, M. Kopanitsa, B. D. Koch, 1994, The Biochemical journal.

Drug Discovery Strategies for Neglected Tropical Diseases: Repurposing Knowledge, Mechanisms and Therapeutics to Increase Discovery Efficiency

D. Swinney, M. Pollastri, 2019, Neglected Tropical Diseases.

Azalanstat (RS-21607), a lanosterol 14α-demethylase inhibitor with cholesterol-lowering activity

R. Heller, D. Swinney, S. Murakami, 1995 .

Steady-state kinetic characterization of kinase activity and requirements for Mg2+ of interleukin-1 receptor-associated kinase-4.

D. Swinney, Mohammad Hekmat-Nejad, Terrence Z. Cai, 2010, Biochemistry.

Opportunities to minimise risk in drug discovery and development

D. Swinney, 2006, Expert opinion on drug discovery.

A Four-Point Screening Method for Assessing Molecular Mechanism of Action (MMOA) Identifies Tideglusib as a Time-Dependent Inhibitor of Trypanosoma brucei GSK3β

D. Swinney, Brad A. Haubrich, P. Guyett, 2016, PLoS neglected tropical diseases.

Experimental Methods to Determine Binding Kinetics

D. Swinney, W. Huber, G. Vauquelin, 2015 .

Applications of Binding Kinetics to Drug Discovery

D. Swinney, Dr David C. Swinney, 2012, Pharmaceutical Medicine.

Drug Discoveries and Molecular Mechanism of Action

D. Swinney, 2015 .

Cloning and functional expression of the cDNA encoding rat lanosterol 14-alpha demethylase.

K. Jarnagin, D. Swinney, O. So, 1995, Gene.

Biochemical Mechanisms of New Molecular Entities (NMEs) approved by United States FDA during 2001‐2004: Mechanisms leading to optimal efficacy and safety.

D. Swinney, David C Swinney, 2006, Current topics in medicinal chemistry.

The Role of Binding Kinetics in GPCR Drug Discovery.

D. Swinney, G. Vauquelin, Brad A. Haubrich, 2015, Current topics in medicinal chemistry.

Radioligand binding to intact cells as a tool for extended drug screening in a representative physiological context.

D. Swinney, G. Vauquelin, I. Van Liefde, 2015, Drug discovery today. Technologies.

How were new medicines discovered?

D. Swinney, J. Anthony, 2011, Nature Reviews Drug Discovery.

Radioligand binding to intact cells as a tool for extended drug screening in a representative physiological context.

D. Swinney, G. Vauquelin, I. Van Liefde, 2015, Drug discovery today. Technologies.

The value of translational biomarkers to phenotypic assays

D. Swinney, 2014, Front. Pharmacol..

Opportunities for phenotypic screening_Layout 1

D. Swinney, 2014 .

Bi-substrate kinetic analysis of an E3-ligase-dependent ubiquitylation reaction.

Michael J. Rose, D. Swinney, Ina Lee, 2005, Methods in enzymology.

Successful drug discovery.

D. Swinney, 2021, Current topics in medicinal chemistry.

The discovery of medicines for rare diseases.

D. Swinney, S. Xia, 2014, Future medicinal chemistry.

Development of a Bioluminescent High-Throughput Screening Assay for Nicotinamide Mononucleotide Adenylyltransferase (NMNAT)

D. Swinney, Brad A. Haubrich, C. Ramesha, 2019, SLAS discovery : advancing life sciences R & D.